Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial

Karl Lewis, Reinhard Dummer, Aaron S Farberg, Alexander Guminski, Nicholas Squittieri, Michael Migden, Karl Lewis, Reinhard Dummer, Aaron S Farberg, Alexander Guminski, Nicholas Squittieri, Michael Migden

Abstract

Introduction: Sonidegib is a Hedgehog pathway inhibitor approved to treat locally advanced basal cell carcinoma and, depending on regulatory approval, metastatic basal cell carcinoma. Results from the BOLT study demonstrated robust efficacy and continued tolerability through 42 months. This analysis evaluated the impact of sonidegib dose reductions and interruptions in patients with advanced basal cell carcinoma through 42 months.

Methods: BOLT was a randomized, double-blind, multicenter, phase 2 study. Adults with no previous Hedgehog pathway inhibitor therapy were randomized 1:2 to sonidegib 200 or 800 mg once daily. Primary endpoint was objective response rate. Dose modifications were permitted in patients unable to tolerate the dosing schedule or if a treatment-related adverse event was suspected.

Results: The incidence of dose interruptions was similar between the 200- and 800-mg groups (68.4% vs 65.3%, respectively). Dose reductions occurred more frequently in patients receiving sonidegib 800 mg (36.7%) than 200 mg (16.5%). Overall response rate for all patients receiving sonidegib 200 mg daily was 48.1% and was similar to those of patients without dose reduction or interruption (48.5%) and patients with at least one dose reduction or interruption (46.2%).

Conclusion: Dose reductions and interruptions were practical and did not impact the efficacy of sonidegib. In patients with advanced basal cell carcinoma who necessitate long-term treatment, dose interruptions may be beneficial for continued treatment and disease control.

Trial registration: ClinicalTrials.gov identifier, NCT01327053.

Keywords: Basal cell carcinoma; Dose interruption; Dose reduction; Hedgehog pathway inhibitor; Sonidegib.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Dose modification steps for sonidegib

References

    1. Bakshi A, Chaudhary SC, Rana M, Elmets CA, Athar M. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond. Mol Carcinog. 2017;56(12):2543–2557. doi: 10.1002/mc.22690.
    1. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–179.
    1. Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014;111(8):1476–1481. doi: 10.1038/bjc.2014.270.
    1. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–754. doi: 10.1038/nrc2503.
    1. Odomzo (sonidegib capsules). Full Prescribing Information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ, USA.
    1. European Medicines Agency. Summary of Product Characteristics, WC500188762.
    1. Swissmedic, Authorization Number 65065. 2015.
    1. Australian Government Department of Health, ARTG 292262.
    1. Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369–1378. doi: 10.1111/bjd.18552.
    1. Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372–381. doi: 10.1111/jdv.14542.
    1. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–728. doi: 10.1016/S1470-2045(15)70100-2.
    1. Lacouture ME, Dréno B, Ascierto PA, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218–1229. doi: 10.1634/theoncologist.2016-0186.
    1. Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404–412. doi: 10.1016/S1470-2045(17)30072-4.
    1. Dummer R, Basset-Seguin N, Hansson J, et al. Impact of treatment breaks on vismodegib patient outcomes: exploratory analysis of the STEVIE study. J Clin Oncol. 2015;33(15_suppl):9024.
    1. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 Published: May 28, 2009 (v4. 03: June 14, 2010). 2016.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다